O

Oura

Makes smart rings for sleep and recovery

Director – Technology Business Operations

Full-Time
$164.9k - $236k+ Equity packages
Expert
San Francisco, CA, USA
HybridHybrid role based out of the San Francisco office.
Business & StrategyBusiness Operations

About the job

Requirements
  • 12+ years of IT experience, including 4+ years leading IT strategy for a fast-growing company, covering value assessments, prioritization frameworks, multi-year planning, and judgment in scaling technology investment alongside the business.
  • Familiarity with Technology Business Management (TBM) or a comparable technology operating model for governing spend, portfolio, and value.
  • Experience partnering with FP&A, Procurement/Legal, Enterprise Architecture, and cross-functional stakeholders without owning their processes.
  • Executive-level communication skills, including owning how the department presents itself upward and outward.
  • Ability to build strategic planning, financial, and governance processes from scratch in a cross-functional environment, and to operate hands-on as the sole builder and manager of a small team before it scales to FTEs.
  • Ability to maintain scope as the strategic and prioritization layer without taking on architecture, delivery, or platform ownership belonging to other functions.
  • Daily use of LLM assistants or agents (such as Claude) for research, drafting, analysis, and problem-solving, with judgment about appropriate use and verification of outputs.
  • Ability to identify recurring processes suitable for AI-assisted work and incorporate that approach into team workflows.
Responsibilities
  • Own IT's strategic planning, prioritization, and governance layer while architecture, delivery, data platforms, cloud infrastructure, and AI enablement remain with their existing teams.
  • Manage a two-resource contractor bridge during the build-out, then hire, lead, and develop a target-state team of two to three full-time employees.
  • Build IT's annual planning cycle, multi-year technology plan, business cases, and investment narratives to support funding and prioritization decisions.
  • Establish a visible prioritization and governance model for IT work and decision-making.
  • Own financial operations in partnership with FP&A, including the cost-center model, contractor versus FTE spend, named application ownership, forecast inputs, and consolidated IT spend and renewal exposure; provide inputs to FP&A's monthly variance review without becoming a purchasing approval gate.
  • Own procurement, contract, and renewal management, including a renewal calendar, negotiation packets, and an application inventory with a named service owner per application.
  • Administer contractor and SOW processes and workforce operations, including requisition tracking and onboarding readiness across multiple countries.
  • Run IT's executive operating cadence, including all-hands, monthly updates, quarterly roadmap reviews, IT Leadership team meetings, and business reviews.

About the company

Oura designs smart rings and a companion app for people who want to understand their sleep, activity, stress, and recovery. Its ring measures signals such as heart rate, movement, and temperature while fitting into daily life without a screen on the wrist. The app turns these daily measurements into sleep and readiness scores, compares changes with a personal baseline, and suggests habits that support rest and activity. Oura sells rings through its website and retail partners, while paid memberships unlock detailed app insights and guidance beyond the basic scores. Founded in Finland in 2013, Oura is headquartered in San Francisco, United States.

Company Size

1,001-5,000

Company Stage

Series E

Total Funding

$1.5B

Headquarters

Oulu, Finland

Founded

2013

Get referred to Oura

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Oura funded expansion: its October 2025 Fidelity-led round raised over $900 million for distribution and product development.
  • Paid memberships persist: Oura's weighted-average twelve-month retention reached 85% by June 2026.
  • Oura's California teams get recovery time: San Francisco and San Diego benefits include eight flexible wellness days.

What critics are saying

  • Oura remains hardware dependent: ring sales generated 83% of fiscal 2025 revenue.
  • Oura's illness alerts have limits: Health Radar is for wellness and expressly excludes disease diagnosis or treatment.
  • Oura's sensor testing requires lab presence: its San Francisco engineer listing specifies onsite work and collaboration across time zones.

What makes Oura unique

  • Oura houses its own scientific bench: more than 50 PhDs work in an interdisciplinary science team.
  • Oura connects nighttime data to contraception: Natural Cycles analyzes its temperature trends through a separate birth control subscription.
  • Oura licenses its smart ring inventions: its patent portfolio includes a multiyear agreement with rival Circular.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Competitive salary & equity packages
  • Health, dental, financial, & vision insurance
  • Wellness & mental health benefits
  • $300 per month health improvement related stipend
  • Flexible working hours
  • An Oura Ring of your own
  • Employee discount for friends & family
  • 20 days of PTO

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

7%

2 year growth

0%
Egerin
Oct 20th, 2026
Oura adds new fitness metrics to show how workouts impact your body | TechCrunch.

Oura adds new fitness metrics to show how workouts impact your body | TechCrunch. As competition in the smart ring market escalates, Oura is introducing two new features to give people more insight into their workouts and how they impact their bodies. The company announced on Tuesday it's rolling out Cardio Effort and VO[2] max metrics to expand workout tracking beyond exercise duration and heart rate zones. While Oura has largely dominated the smart ring market for years, rivals like RingConn and Ultrahuman are emerging to dethrone it, putting pressure on the company to keep innovating. By launching more advanced workout metrics, Oura is looking to differentiate itself from competitors. With Cardio Effort, users will be able to see how much a workout taxes their cardiovascular system. This measurement is aggregated over the week relative to each user's individual baseline to provide more insights. Oura explained that this metric shifts users' focus from "How many minutes did I move?" to "Am I maintaining my fitness, building it, or overdoing it?" Since Cardio Effort accounts for both intensity and duration, a shorter, more intense workout can yield a similar score to a longer, less intense one, the company says. Oura notes that the metric has two components: Workout Cardio Effort and Weekly Cardio Effort. The first metric evaluates the impact of an individual workout, while the latter aggregates effort into a weekly total, categorized as "Light," "Fair," "Maintaining," "Building," or "Reaching." Oura measures elevated heart rate relative to each member's long-term resting heart rate, avoiding the variability associated with maximum-heart-rate estimates. Weekly effort levels are then determined using personalized ranges based on recent activity patterns. Cardio Effort is rolling out to Oura Ring Gen3 and later models. As for VO[2] max, the metric shows how workouts contribute to long-term fitness. It measures how effectively the heart, lungs, and muscles work together to deliver and use oxygen during exercise. Previously, measuring VO[2] max typically required a lab test or a six-minute walking test. Oura can now estimate it passively using GPS-enabled workouts. After completing five qualifying activities, users receive an initial VO2 Max estimate. Within the My Health Heart Hub, they can view their current VO2 Max estimate in ml/kg/min, their fitness category (Low, Fair, High, or Peak), how their estimate has changed over time, and when it was last updated. Users also receive insights highlighting meaningful changes in their VO2 Max or indicating when their estimate remains consistent. VO[2] Max is launching in Oura Labs, the company's hub for experimental features, for members with Gen3 and newer Oura Ring devices. Oura says these two new features are designed to work together to show users how hard they're working and how that effort is adding up over time. When you purchase through links in its articles, Egerin Inc. may earn a small commission. This doesn't affect its editorial independence. Aisha is a consumer news reporter at TechCrunch. Prior to joining the publication in 2021, she was a telecom reporter at MobileSyrup. Aisha holds an honours bachelor's degree from University of Toronto and a master's degree in journalism from Western University. You can contact or verify outreach from Aisha by emailing [email protected] or via encrypted message at aisha_malik.01 on Signal.

Stuff
Oct 11th, 2026
Beyond the period tracker: how wearables are finally getting hormones right, and who does it best.

Beyond the period tracker: how wearables are finally getting hormones right, and who does it best. From temperature-sensing smart rings to menopause tracking on your wrist, wearables are finally taking hormonal health seriously 11 October 2026 / 18:50 BST For years, women's health on a fitness tracker meant a glorified period calendar. You logged your flow manually (requiring you to remember to do so), and you'd get a vague prediction for the following month (only helpful for those with regular cycles). That was about it. The same device would happily tell you your VO2 Max to two decimal places, but when it came to correlating your energy score with your cycle phase, you'd be out of luck. That's finally starting to change (albeit slowly). It hasn't happened because of a single breakthrough, but because several pieces of the puzzle are falling into place. Wearable sensors can now detect subtle overnight temperature shifts, and companies are using AI models trained specifically on reproductive health data rather than treating female health tracking as an afterthought. There's still work to do, but wearables are moving in the right direction for tracking female health and hormonal changes. Here are the leaders and what they offer. Oura. For any woman who has used the Natural Cycles app, it will likely come as no surprise that Oura is one of the companies setting the pace in female cycle tracking. It was the first wearable to partner with the FDA-cleared birth control app, allowing users to wear its smart rings for temperature input instead of using a basal thermometer every morning before getting out of bed. Other wearables also now support Natural Cycles integration, but Oura pipped them all to the post in 2022. This year, ahead of the Oura Ring 5 launch, the Finnish company introduced Menopause Insights. It centres on the Menopause Impact Scale, a questionnaire developed by Oura to measure how 22 symptoms affect quality of life and daily functioning. Oura combines your answers with your long-term biometric data to explain your results, show how symptoms correlate with trends such as HRV and sleep disturbances, and track changes over time. For cycle tracking, Oura also released an AI model trained specifically on reproductive health data and added the option to tell the app which birth control method you are using (hormonal or non-hormonal), if any. By entering this information, the app takes it into account to deliver more accurate and relevant insights. Oura uses temperature data to predict ovulation, helping not only to tell you what stage of your cycle you are in and what that might mean for metrics like your heart rate and HRV, but also to identify which days you're most likely to conceive. It also has an AI-powered advisor, allowing users to ask questions about their data and cycle to help them make sense of the information being presented to them. Ultrahuman. Ultrahuman takes a similar approach to Oura, continuously tracking temperature with its smart rings - Ring Air and Ring Pro - to provide insights into the female cycle. Unlike Oura, which has a monthly subscription, Ultrahuman doesn't require one. However, there is the option to add paid PowerPlugs, including the Cycle & Ovulation Pro, which costs $3.99 a month. The free cycle tracking included with Ultrahuman uses temperature to predict ovulation and determine your cycle phase, with helpful insights to explain what that might mean. The Cycle & Ovulation Pro PowerPlug takes this several steps further. It uses the same sensors as the free version but, following the company's acquisition of viO HealthTech (a medical device company behind the OvuSense fertility monitor), adapts viO's temperature-sensing algorithm, developed over 15 years and trained on more than 260,000 cycles collected with medical-grade sensors. Ultrahuman says Pro confirms ovulation with more than 90 per cent accuracy, based on its own testing against LH and progesterone rises. It's aimed at people whose cycles don't follow the textbook 28-day cycle, including those with PCOS or endometriosis, though it isn't FDA-cleared or intended for contraception. Another notable feature is Cycle Flags, which analyses temperature data for patterns rather than making single-cycle predictions: for example, consistently early or late ovulation, a shortened luteal phase, or cycles where ovulation doesn't appear to occur at all. None of that is diagnostic - Ultrahuman is explicit that Pro is a wellness tool, not a substitute for clinical testing - but surfacing a recurring pattern over several months could be a helpful piece of information to bring to a doctor, rather than something you'd notice from period-diary logging alone. Whoop. Historically the most performance-obsessed of the bunch, Whoop leans more on lab work than its rivals. Its Hormonal Symptom Insights and Predictions, announced in March of this year, build a personalised model of your cycle from your physiological data and history. The model adapts over time, widening or narrowing its forecast as it learns how variable your cycles are. Whoop says it accounts for irregular cycles, perimenopause and hormonal birth control. Whoop Advanced Labs adds a Women's Health panel of 81 biomarkers, including 11 female-specific ones: AMH, progesterone, prolactin, thyroid markers, leptin, B12, folate, magnesium and phosphorus. Testing is conducted at Quest Diagnostics locations, with results reviewed by a licensed clinician. The panel is sold separately and is US-only, so unfortunately for anyone this side of the pond, you can't benefit from it just yet. For those in the US, results are tied back to your cycle, with reference ranges matched to your cycle phase and sorted into optimal, sufficient or out of range. Whoop says this helps with perimenopause, thyroid function and nutrient levels, which it says standard testing often under-measures. It has published a white paper on its modelling, so if you fancy some bedtime reading. Apple Watch. Apple takes a slightly more cautious approach than the others I've mentioned so far. Its Cycle Tracking app (also in the Health app on iPhone) logs periods, symptoms, spotting and basal body temperature, then predicts your next period and a six-day fertile window. Predictions rely on what you log, and the fertile window uses the traditional calendar method. Heart rate data from the Watch, enabled by default, further refines predictions, and on compatible models, overnight wrist temperature is used to estimate ovulation retrospectively, improving predictions. Menopause support has also been introduced with the latest software - iOS 27 and watchOS 27. For users aged 40 and over, Cycle Tracking can notify you when your logged cycles suggest perimenopause. In the Health app on iPhone, you can then log perimenopause or menopause and track symptoms such as hot flushes, night sweats and sleep changes. Once menopause is logged, predictions and fertile window estimates are disabled. None of the devices mentioned above measure hormones directly. They infer hormone levels from temperature, heart rate and HRV, and illness, alcohol, travel or a bad night's sleep can all muddy the signal. A wearable can't always distinguish ovulation from a rough night, which is why pretty much every brand stresses that its features are for wellness, not diagnosis. The next step may be dedicated hormone monitoring. Clair Health is developing a wearable that it says reads hormone patterns from more than 130 physiological signals, using machine learning trained on paired hormone data. That's still inference rather than direct measurement, and it isn't on sale yet, with devices due in January 2027. For now, then, what's above is what is available. They might not be perfect, but it's a lot better than what it was even a couple of years ago, so Stuff is on the right track. Britta O'Boyle About. Britta has covered the consumer tech industry since 2012. Her specialties include smartphones, smart home, speakers and wearables.

Bandt
Oct 9th, 2026
ŌURA to 'vigorously defend' lawsuit alleging deceptive sleep tracking marketing claims.

ŌURA to 'vigorously defend' lawsuit alleging deceptive sleep tracking marketing claims. Published on: 9th October 2026 at 11:50 AM Wearable tech brand ŌURA has said it will "vigorously defend" allegations that it misled consumers through marketing claims about the accuracy of its sleep tracking technology. The lawsuit, filed on 20 August in the US District Court for the Northern District of California by plaintiff Madison Surber through the Clarkson Law Firm, alleges that ŌURA overstated the accuracy of its sleep tracking capabilities and deceptively marketed its smart rings as being able to accurately measure different stages of sleep. The case argues that sleep staging requires monitoring brain waves, eye movements and muscle tone, rather than relying solely on the heart rate, movement and temperature data detected by a ring. The allegations specifically target ŌURA's marketing claims, including assertions that its devices achieve between 79 and 95 per cent accuracy in sleep staging compared to clinical sleep labs. The plaintiff alleges that ŌURA's rings lack neurological and ocular sensors, such as brain wave or eye movement monitors, and instead rely on peripheral data and artificial intelligence (AI) and machine learning estimates. The lawsuit contends this approach can be no better than a coin flip under certain conditions. The filing accuses ŌURA of misrepresenting "faulty AI-based inference as reliable science" and taking advantage of consumers who struggle with sleep or have health concerns. The lawsuit claims the marketing messages were spread across several channels, including ŌURA's websites, retail partners and social media, with the plaintiff alleging the brand presented its sleep tracking capabilities as offering near-clinical levels of accuracy. ŌURA officially launched in 2013 and released its first-generation ring in 2015. Its fifth-generation ring was launched in June this year. In Australia, Oura Ring 5 in Gold, is currently being sold for A $799 on their official website. The case explains that the ŌURA Ring 4, ŌURA Ring 4 Ceramic and ŌURA Ring 5 models at issue, contrary to the defendants' marketing claims, merely "infer sleep stage data" based on heart rate, physical movement, peripheral skin temperature and, depending on the model, blood oxygen trends. None of these measures neurological activity. According to Surber, accurately tracking sleep metrics must involve, among other things, electrodes connected to the scalp and sensors on the eyes and chin, which are typically used in a hospital or laboratory setting. The case emphasises that "sleep happens in the brain, not on one's finger" and argues that the "unparalleled accuracy" claims touted by ŌURA are unfounded in light of the rings' limitations. It adds that "Oura did not just claim to measure a heartbeat or a temperature, but the exact stage of sleep the wearer is in - which in reality requires electrodes in the scalp and sensors on the eyes, as only a hospital or other clinical setting can do. Yet Oura claimed that their ring - which uses no such technology - delivers 'unparalleled accuracy'." In the filing, Surber also alleges that marketing messages promising near-100 per cent accuracy in sleep stage tracking "were spread across every channel Oura controls", including its websites, retail partners and social media. In an interview with The Daily Telegraph, Ricky Bloomfield, ŌURA's chief medical officer (CMO) said ŌURA stood by its data and accuracy claims, highlighting the release of publicly available research supporting its technology. "We will vigorously defend against those in the appropriate legal forum," he said. Bloomfield said ŌURA did not make diagnostic tools, and its devices were designed to provide customers with information that raises awareness about various disorders and leads to more informed discussions with doctors and other health professionals. "We don't have enough primary care physicians, and those that we do have feel like they're overworked and they don't have a lot of time to spend. And so, oftentimes, when someone comes in with a very specific concern supported by data, it often helps to short circuit a lot of the discussion for clinicians, so that they can focus in on the questions that they need the answers to then get to a diagnosis," Bloomfield added. In a similar case earlier this year oral healthcare brand Hi Smile was forced to cough up $138,600 in penalties by Australian Competition and Consumer Commission (ACCC) as a result of misleading social media advertising. An official trial start date has not yet been scheduled for the Surber v. Oura lawsuit, with legal proceedings remaining in the early stages. Join more than 30,000 advertising industry experts Get all the latest advertising and media news direct to your inbox from B&T.

Gizmodo
Sep 30th, 2026
Qalo's screenless health tracker has a Smart Ring companion, too.

Qalo's screenless health tracker has a Smart Ring companion, too. Qalo's new subscription-free fitness SL-1 Smart Band works on its own as a Whoop competitor but is even better when paired with the company's smart ring. Reading time 2 minutes Qalo, maker of a subscription-free smart ring competitor to Oura, apparently has Whoop in its crosshairs, too. The company just announced the SL-1 Smart Band, a new screenless wearable device for your wrist that tracks all the same health data as the company's SR-2 Smart Ring, allowing you to seamlessly switch between them depending on the scenario. The strategy is an increasingly common one in a wearable space where capturing as much data as possible is the goal, and Qalo makes it more compelling by being relatively affordable. The SL-1 is a small rectangular puck of sensors that looks similar to a Whoop 5.0 or competing devices like the Garmin Cirqa, which can be fitted with a variety of silicone and fabric wristbands. Qalo says the device is water-resistant up to around 30 feet and can last over 12 days on a single charge (qualities that will have to be tested in a review), but if you're drawn to the minimalism of screenless wearables, it seems to fit the bill. More importantly, all of the health tracking basics are covered: The SL-1 can monitor your sleep, movement, blood-oxygen levels, heart rate, heart rate variability, stress, skin temperature, and menstrual cycles, all without a subscription. Qalo combines that data into a daily "Q Score" that gives you a sense of your health that day and also offers things like menstrual prediction and automatic workout detection. The real draw of the SL-1 is how it works with Qalo's SR-2 Smart Ring, though. Both devices contribute data to the same health profile, making it possible to switch which device you're wearing without losing data in the process. Qalo imagines its rings working for most people during the day or as a more comfortable option while you're sleeping, with the SL-1 band being for more intense workouts or activities where you need your hands and fingers free. Samsung has pitched wearing its Galaxy Ring and Galaxy Watch together using the same logic. The lightweight Galaxy Ring works on its own, but it's even more useful as the wearable you turn to when you don't want a large screen on your wrist. Google's Fitbit Air could serve the same purpose for anyone who already owns a Pixel Watch. Qalo might not be able to deliver hardware and software at the level of Samsung or Google, but its devices could still be a good alternative because they're relatively inexpensive. The SL-1 Smart Band and SR-2 Smart Ring each retail for $200, meaning you can purchase them both for around the price of an Apple Watch Series 12. For anyone trying to capture as much data as possible, that could be a lot easier to swallow.

Yahoo Finance
Sep 29th, 2026
Oura postpones IPO, citing 'uncertainty' in the market.

Oura postpones IPO, citing 'uncertainty' in the market. Aaron McDade Key takeaways. * Oura postponed its debut on the Nasdaq, citing uncertainty in the IPO market. * The health-tracking ring maker said it remains profitable and reported strong investor demand. Investors will have to wait a bit longer to own a piece of a hot health tracking device maker. Oura is postponing its IPO, citing "uncertainty in the IPO market." The company said Tuesday that it made the decision to delay its market debut despite being profitable and seeing "strong demand" for its shares. "An IPO is just one step in our journey," Oura CEO Tom Hale said in a statement. "We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment. In the meantime, we will execute against the opportunities ahead." Oura, which was founded in Finland in 2013, sells health tracking rings and also offers a subscription service that gives users additional data about sleep and other health and wellness metrics. The firm had planned to debut on the Nasdaq with the "OURA" stock ticker soon after revealing its prospectus last week. In the prospectus, Oura said it generated $1.2 billion in sales and $60.77 million in profits in the first three quarters of its current fiscal year. That's up from $697.57 million in revenue and $1.57 million in earnings in the same period last year. Read the original article on Investopedia